|
1
|
Sabit H, Cevik E and Tombuloglu H:
Colorectal cancer: The epigenetic role of microbiome. World J Clin
Cases. 7:3683–3697. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Fakih MG: Metastatic colorectal cancer:
Current state and future directions. J Clin Oncol. 33:1809–1824.
2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Simon K: Colorectal cancer development and
advances in screening. Clin Interv Aging. 11:967–976.
2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297.
2004.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Valenti MT, Dalle Carbonare L and Mottes
M: Role of microRNAs in progenitor cell commitment and osteogenic
differentiation in health and disease (Review). Int J Mol Med.
41:2441–2449. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gentilin E, Degli Uberti E and Zatelli MC:
Strategies to use microRNAs as therapeutic targets. Best Pract Res
Clin Endocrinol Metab. 30:629–639. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Momtazi AA, Shahabipour F, Khatibi S,
Johnston TP, Pirro M and Sahebkar A: Curcumin as a microRNA
regulator in cancer: A review. Rev Physiol Biochem Pharmacol.
171:1–38. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 9(852)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Asadzadeh Z, Mansoori B, Mohammadi A,
Aghajani M, Haji-Asgarzadeh K, Safarzadeh E, Mokhtarzadeh A, Duijf
PHG and Baradaran B: microRNAs in cancer stem cells: Biology,
pathways, and therapeutic opportunities. J Cell Physiol.
234:10002–10017. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Kwak PB, Iwasaki S and Tomari Y: The
microRNA pathway and cancer. Cancer Sci. 101:2309–2315.
2010.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115.
2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Qu H, Xu W, Huang Y and Yang S:
Circulating miRNAs: Promising biomarkers of human cancer. Asian Pac
J Cancer Prev. 12:1117–1125. 2011.PubMed/NCBI
|
|
16
|
Hosseinahli N, Aghapour M, Duijf PHG and
Baradaran B: Treating cancer with microRNA replacement therapy: A
literature review. J Cell Physiol. 233:5574–5588. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wang B, Lu FY, Shi RH, Feng YD, Zhao XD,
Lu ZP, Xiao L, Zhou GQ, Qiu JM and Cheng CE: MiR-26b regulates
5-FU-resistance in human colorectal cancer via down-regulation of
Pgp. Am J Cancer Res. 8:2518–2527. 2018.PubMed/NCBI
|
|
18
|
Wang W, He Y, Rui J and Xu MQ: miR-410
acts as an oncogene in colorectal cancer cells by targeting
dickkopf-related protein 1 via the Wnt/β-catenin signaling pathway.
Oncol Lett. 17:807–814. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Muhammad S, Tang Q, Wei L, Zhang Q, Wang
G, Muhammad BU, Kaur K, Kamchedalova T, Gang Z, Jiang Z, et al:
miRNA-30d serves a critical function in colorectal cancer
initiation, progression and invasion via directly targeting the
GNA13 gene. Exp Ther Med. 17:260–272. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Xu C, Li S, Chen T, Hu H, Ding C, Xu Z,
Chen J, Liu Z, Lei Z, Zhang HT, et al: miR-296-5p suppresses cell
viability by directly targeting PLK1 in non-small cell lung cancer.
Oncol Rep. 35:497–503. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lee KH, Lin FC, Hsu TI, Lin JT, Guo JH,
Tsai CH, Lee YC, Lee YC, Chen CL, Hsiao M, et al: MicroRNA-296-5p
(miR-296-5p) functions as a tumor suppressor in prostate cancer by
directly targeting Pin1. Biochim Biophys Acta. 1843:2055–2066.
2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Benson AB III, Venook AP, Al-Hawary MM,
Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D,
Engstrom PF, et al: NCCN Guidelines Insights: Colon Cancer, Version
2.2018. J Natl Compr Canc Netw. 16:359–369. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wong N and Wang X: miRDB: An online
resource for microRNA target prediction and functional annotations.
Nucleic Acids Res. 43 (D1):D146–D152. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Deng Z, Yan F, Jin Q, Wu J, Liu X and
Zheng H: Reversal of multidrug resistance phenotype in human breast
cancer cells using doxorubicin-liposome-microbubble complexes
assisted by ultrasound. J Control Release. 174:109–116.
2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Shi DM, Li LX, Bian XY, Shi XJ, Lu LL,
Zhou HX, Pan TJ, Zhou J, Fan J and Wu WZ: miR-296-5p suppresses EMT
of hepatocellular carcinoma via attenuating NRG1/ERBB2/ERBB3
signaling. J Exp Clin Cancer Res. 37(294)2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Maia D, de Carvalho AC, Horst MA, Carvalho
AL, Scapulatempo-Neto C and Vettore AL: Expression of miR-296-5p as
predictive marker for radiotherapy resistance in early-stage
laryngeal carcinoma. J Transl Med. 13(262)2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Li T, Lu YY, Zhao XD, Guo HQ, Liu CH, Li
H, Zhou L, Han YN, Wu KC, Nie YZ, et al: MicroRNA-296-5p increases
proliferation in gastric cancer through repression of
Caudal-related homeobox 1. Oncogene. 33:783–793. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lee H, Shin CH, Kim HR, Choi KH and Kim
HH: MicroRNA-296-5p promotes invasiveness through downregulation of
nerve growth factor receptor and Caspase-8. Mol Cells. 40:254–261.
2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Conte A, Paladino S, Bianco G, Fasano D,
Gerlini R, Tornincasa M, Renna M, Fusco A, Tramontano D and
Pierantoni GM: High mobility group A1 protein modulates autophagy
in cancer cells. Cell Death Differ. 24:1948–1962. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Liu L, Zhang S, Hu L, Liu L, Guo W and
Zhang J: HMGA1 participates in MHCC97H cell proliferation and
invasion through the ILK/Akt/GSK3β signaling pathway. Mol Med Rep.
16:9287–9294. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Colamaio M, Tosti N, Puca F, Mari A,
Gattordo R, Kuzay Y, Federico A, Pepe A, Sarnataro D, Ragozzino E,
et al: HMGA1 silencing reduces stemness and temozolomide resistance
in glioblastoma stem cells. Expert Opin Ther Targets. 20:1169–1179.
2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kim DK, Seo EJ, Choi EJ, Lee SI, Kwon YW,
Jang IH, Kim SC, Kim KH, Suh DS, Seong-Jang K, et al: Crucial role
of HMGA1 in the self-renewal and drug resistance of ovarian cancer
stem cells. Exp Mol Med. 48(e255)2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Quintavalle C, Burmeister K, Piscuoglio S,
Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM,
Andersen JB, Pallante P, et al: High mobility group A1 enhances
tumorigenicity of human cholangiocarcinoma and confers resistance
to therapy. Mol Carcinog. 56:2146–2157. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
35
|
Loria R, Laquintana V, Bon G, Trisciuoglio
D, Frapolli R, Covello R, Amoreo CA, Ferraresi V, Zoccali C,
Novello M, et al: HMGA1/E2F1 axis and NFkB pathways regulate LPS
progression and trabectedin resistance. Oncogene. 37:5926–5938.
2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lin Y, Chen H, Hu Z, Mao Y, Xu X, Zhu Y,
Xu X, Wu J, Li S, Mao Q, et al: miR-26a inhibits proliferation and
motility in bladder cancer by targeting HMGA1. FEBS Lett.
587:2467–2473. 2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhang X, Tao T, Liu C, Guan H, Huang Y, Xu
B and Chen M: Downregulation of miR-195 promotes prostate cancer
progression by targeting HMGA1. Oncol Rep. 36:376–382.
2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zhou WB, Zhong CN, Luo XP, Zhang YY, Zhang
GY, Zhou DX and Liu LP: miR-625 suppresses cell proliferation and
migration by targeting HMGA1 in breast cancer. Biochem Biophys Res
Commun. 470:838–844. 2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Jia XP, Meng LL, Fang JC, Wang HW, Chen J,
Zhou J, Wang CN and Jiang WF: Aberrant expression of miR-142-3p and
its target gene HMGA1 and FZD7 in breast cancer and its clinical
significance. Clin Lab. 64:915–921. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Liu J, Mi B, Wang Y, Shi C, Mi X, Lu Y and
Yu P: miR-26a suppresses osteosarcoma migration and invasion by
directly targeting HMGA1. Oncol Lett. 15:8303–8310. 2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Chandrasekaran KS, Sathyanarayanan A and
Karunagaran D: MicroRNA-214 suppresses growth, migration and
invasion through a novel target, high mobility group AT-hook 1, in
human cervical and colorectal cancer cells. Br J Cancer.
115:741–751. 2016.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Lopez-Bertoni H, Lal B, Michelson N,
Guerrero-Cázares H, Quiñones-Hinojosa A, Li Y and Laterra J:
Epigenetic modulation of a miR-296-5p:HMGA1 axis regulates Sox2
expression and glioblastoma stem cells. Oncogene. 35:4903–4913.
2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Chaudhary S, Islam Z, Mishra V, Rawat S,
Ashraf GM and Kolatkar PR: Sox2: A Regulatory Factor in
Tumorigenesis and Metastasis. Curr Protein Pept Sci. 20:495–504.
2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Xi Y, Li YS and Tang HB: High mobility
group A1 protein acts as a new target of Notch1 signaling and
regulates cell proliferation in T leukemia cells. Mol Cell Biochem.
374:173–180. 2013.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Belton A, Xian L, Huso T, Koo M, Luo LZ,
Turkson J, Page BD, Gunning PT, Liu G, Huso DL, et al: STAT3
inhibitor has potent antitumor activity in B-lineage acute
lymphoblastic leukemia cells overexpressing the high mobility group
A1 (HMGA1)-STAT3 pathway. Leuk Lymphoma. 57:2681–2684.
2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Capo A, Sepe R, Pellino G, Milone M,
Malapelle U, Pellecchia S, Pepe F, Cacciola NA, Manigrasso M,
Bruzzaniti S, et al: Setting up and exploitation of a
nano/technological platform for the evaluation of HMGA1b protein in
peripheral blood of cancer patients. Nanomedicine (Lond).
15:231–242. 2019.PubMed/NCBI View Article : Google Scholar
|
